Published in Hepatitis Weekly, September 23rd, 2002
On August 6, the company announced that it had initiated a patent infringement action against Roche in the Netherlands and will be filing a counter-action for patent infringement against Roche in Switzerland where Roche is seeking a declaratory judgment that their marketing of ribavirin does not infringe Ribapharm's patents.
"These legal actions against Roche in Europe underscore Ribapharm's resolve to vigorously enforce and defend our patents," said Johnson Y.N. Lau, MD, president and CEO of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly